| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 16 | 2024 | 638 | 2.120 |
Why?
|
| Kidney Failure, Chronic | 19 | 2024 | 880 | 1.880 |
Why?
|
| Renal Dialysis | 8 | 2023 | 854 | 1.030 |
Why?
|
| Tissue and Organ Procurement | 3 | 2022 | 219 | 0.840 |
Why?
|
| Organ Transplantation | 2 | 2022 | 165 | 0.830 |
Why?
|
| Relative Value Scales | 3 | 2019 | 12 | 0.770 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2022 | 101 | 0.770 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 57 | 0.750 |
Why?
|
| Vesico-Ureteral Reflux | 4 | 2023 | 81 | 0.700 |
Why?
|
| Health Policy | 2 | 2020 | 212 | 0.700 |
Why?
|
| Waiting Lists | 6 | 2024 | 228 | 0.670 |
Why?
|
| Living Donors | 4 | 2022 | 109 | 0.660 |
Why?
|
| Clinical Coding | 2 | 2019 | 13 | 0.660 |
Why?
|
| Peritoneal Dialysis | 6 | 2020 | 119 | 0.640 |
Why?
|
| International Classification of Diseases | 2 | 2019 | 90 | 0.620 |
Why?
|
| Renal Insufficiency | 2 | 2017 | 236 | 0.530 |
Why?
|
| Immunosuppressive Agents | 4 | 2020 | 647 | 0.530 |
Why?
|
| Child | 45 | 2024 | 24476 | 0.520 |
Why?
|
| Graft Survival | 6 | 2022 | 532 | 0.490 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 606 | 0.470 |
Why?
|
| Pediatrics | 6 | 2019 | 1158 | 0.450 |
Why?
|
| Kidney | 13 | 2022 | 1354 | 0.450 |
Why?
|
| Current Procedural Terminology | 3 | 2019 | 5 | 0.450 |
Why?
|
| Peritonitis | 3 | 2009 | 75 | 0.410 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 728 | 0.390 |
Why?
|
| Adolescent | 30 | 2024 | 19339 | 0.370 |
Why?
|
| Phosphorus | 1 | 2011 | 56 | 0.360 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 2022 | 26 | 0.350 |
Why?
|
| Fibroblast Growth Factors | 1 | 2011 | 153 | 0.330 |
Why?
|
| Sodium Hypochlorite | 1 | 2009 | 7 | 0.330 |
Why?
|
| Mupirocin | 1 | 2009 | 19 | 0.330 |
Why?
|
| Calcinosis | 1 | 2011 | 178 | 0.330 |
Why?
|
| Graft Rejection | 5 | 2022 | 590 | 0.320 |
Why?
|
| Child, Preschool | 28 | 2024 | 14055 | 0.280 |
Why?
|
| Humans | 63 | 2024 | 124905 | 0.270 |
Why?
|
| Urogenital Abnormalities | 2 | 2020 | 155 | 0.260 |
Why?
|
| Catheterization | 3 | 2022 | 236 | 0.260 |
Why?
|
| Infant | 26 | 2024 | 12488 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 1030 | 0.250 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 3 | 2017 | 20 | 0.240 |
Why?
|
| Retrospective Studies | 14 | 2024 | 16309 | 0.240 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2014 | 8 | 0.230 |
Why?
|
| Coronary Artery Disease | 1 | 2011 | 769 | 0.230 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2014 | 42 | 0.220 |
Why?
|
| United States | 8 | 2022 | 10884 | 0.220 |
Why?
|
| Male | 40 | 2024 | 61355 | 0.220 |
Why?
|
| Transplants | 1 | 2022 | 35 | 0.200 |
Why?
|
| Female | 34 | 2024 | 66624 | 0.200 |
Why?
|
| Ureteral Obstruction | 1 | 2023 | 105 | 0.190 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2002 | 76 | 0.190 |
Why?
|
| Ureter | 1 | 2023 | 97 | 0.190 |
Why?
|
| Nephrotic Syndrome | 3 | 2018 | 46 | 0.180 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2020 | 9 | 0.180 |
Why?
|
| Hemodialysis, Home | 1 | 2020 | 13 | 0.180 |
Why?
|
| Parenteral Nutrition | 1 | 2002 | 194 | 0.180 |
Why?
|
| Prospective Payment System | 1 | 2020 | 16 | 0.180 |
Why?
|
| Young Adult | 5 | 2020 | 9000 | 0.170 |
Why?
|
| Tissue Donors | 4 | 2022 | 488 | 0.170 |
Why?
|
| Uganda | 1 | 2020 | 68 | 0.170 |
Why?
|
| Urinary Tract Infections | 1 | 2014 | 301 | 0.170 |
Why?
|
| Drug Therapy, Combination | 3 | 2015 | 1163 | 0.160 |
Why?
|
| Vitamin D Deficiency | 1 | 2020 | 73 | 0.160 |
Why?
|
| Treatment Outcome | 9 | 2023 | 12354 | 0.160 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 183 | 0.160 |
Why?
|
| Infant, Newborn | 9 | 2021 | 8196 | 0.150 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 103 | 0.150 |
Why?
|
| Nephrosis, Lipoid | 1 | 2018 | 10 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 295 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2020 | 196 | 0.150 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 129 | 0.150 |
Why?
|
| Hemodiafiltration | 1 | 2017 | 18 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2020 | 371 | 0.140 |
Why?
|
| Age Factors | 6 | 2021 | 2821 | 0.140 |
Why?
|
| Hypertension, Renal | 2 | 2000 | 38 | 0.140 |
Why?
|
| Anemia | 2 | 2020 | 340 | 0.140 |
Why?
|
| Biopsy | 3 | 2018 | 1237 | 0.130 |
Why?
|
| Time Factors | 4 | 2024 | 6313 | 0.130 |
Why?
|
| Cyclosporine | 2 | 2015 | 146 | 0.130 |
Why?
|
| Mycophenolic Acid | 1 | 2015 | 51 | 0.120 |
Why?
|
| Catheterization, Peripheral | 1 | 2017 | 126 | 0.120 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 777 | 0.120 |
Why?
|
| Tacrolimus | 1 | 2015 | 99 | 0.120 |
Why?
|
| Prednisone | 1 | 2015 | 275 | 0.120 |
Why?
|
| Hematuria | 4 | 1993 | 54 | 0.120 |
Why?
|
| Hemolytic-Uremic Syndrome | 4 | 2002 | 35 | 0.110 |
Why?
|
| Growth | 2 | 1994 | 106 | 0.110 |
Why?
|
| Maleates | 4 | 1983 | 14 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 5158 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 776 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3449 | 0.100 |
Why?
|
| Risk Factors | 7 | 2024 | 10281 | 0.100 |
Why?
|
| Adult | 14 | 2022 | 29498 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1425 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1352 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 504 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 943 | 0.090 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2011 | 12 | 0.090 |
Why?
|
| Transplant Recipients | 2 | 2022 | 216 | 0.090 |
Why?
|
| Quality of Life | 1 | 2020 | 1948 | 0.090 |
Why?
|
| Pancreas Transplantation | 1 | 2010 | 36 | 0.080 |
Why?
|
| Medicare Access and CHIP Reauthorization Act of 2015 | 1 | 2019 | 1 | 0.080 |
Why?
|
| Skin Care | 1 | 2009 | 14 | 0.080 |
Why?
|
| Body Weight | 3 | 2004 | 1005 | 0.080 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2019 | 19 | 0.080 |
Why?
|
| Postoperative Care | 1 | 1992 | 297 | 0.080 |
Why?
|
| Disinfectants | 1 | 2009 | 25 | 0.080 |
Why?
|
| Administration, Topical | 1 | 2009 | 141 | 0.080 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 746 | 0.080 |
Why?
|
| Advisory Committees | 1 | 2019 | 154 | 0.080 |
Why?
|
| Growth Disorders | 2 | 1990 | 210 | 0.080 |
Why?
|
| Pseudomonas Infections | 1 | 2009 | 115 | 0.080 |
Why?
|
| Nifedipine | 1 | 1988 | 21 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 5 | 2003 | 503 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 582 | 0.070 |
Why?
|
| Glomerulonephritis, IGA | 1 | 1988 | 16 | 0.070 |
Why?
|
| Kidney Diseases | 3 | 2005 | 482 | 0.070 |
Why?
|
| Enteral Nutrition | 1 | 1990 | 256 | 0.070 |
Why?
|
| Medicaid | 1 | 2019 | 242 | 0.070 |
Why?
|
| Cytomegalovirus | 1 | 1988 | 270 | 0.070 |
Why?
|
| Decision Making | 2 | 1981 | 654 | 0.060 |
Why?
|
| Antigens, Viral | 1 | 1988 | 438 | 0.060 |
Why?
|
| Calcium | 1 | 2011 | 1099 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3151 | 0.060 |
Why?
|
| Kidney Tubules, Proximal | 2 | 1983 | 108 | 0.060 |
Why?
|
| Nephrology | 2 | 2005 | 145 | 0.060 |
Why?
|
| Time | 1 | 2005 | 94 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2019 | 1175 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 558 | 0.060 |
Why?
|
| Antihypertensive Agents | 3 | 2000 | 412 | 0.060 |
Why?
|
| Ultrafiltration | 1 | 2004 | 13 | 0.060 |
Why?
|
| Creatinine | 2 | 2003 | 390 | 0.060 |
Why?
|
| Home Nursing | 1 | 1983 | 16 | 0.060 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 174 | 0.060 |
Why?
|
| Health Services Research | 1 | 2005 | 188 | 0.060 |
Why?
|
| Drug Resistance, Microbial | 1 | 2014 | 193 | 0.050 |
Why?
|
| Kidney Tubules, Distal | 1 | 1983 | 17 | 0.050 |
Why?
|
| Nephrons | 1 | 1983 | 20 | 0.050 |
Why?
|
| Blood Volume | 1 | 2004 | 80 | 0.050 |
Why?
|
| Kidney Tubules | 1 | 1983 | 82 | 0.050 |
Why?
|
| Hypertension | 2 | 1991 | 1317 | 0.050 |
Why?
|
| Acute Kidney Injury | 2 | 2005 | 634 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2092 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 2906 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2014 | 217 | 0.050 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2002 | 33 | 0.050 |
Why?
|
| Hepatitis B Vaccines | 1 | 2002 | 41 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2002 | 110 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 241 | 0.050 |
Why?
|
| Fever | 1 | 2014 | 295 | 0.050 |
Why?
|
| Recurrence | 2 | 2018 | 1427 | 0.050 |
Why?
|
| Iron | 1 | 2004 | 268 | 0.050 |
Why?
|
| Hepatitis B virus | 1 | 2002 | 136 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2005 | 689 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2002 | 317 | 0.050 |
Why?
|
| Hepatitis B | 1 | 2002 | 160 | 0.040 |
Why?
|
| Protective Factors | 1 | 2021 | 85 | 0.040 |
Why?
|
| Fee Schedules | 2 | 2014 | 2 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2022 | 661 | 0.040 |
Why?
|
| Fanconi Syndrome | 3 | 1982 | 9 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1639 | 0.040 |
Why?
|
| Pneumococcal Infections | 1 | 2002 | 274 | 0.040 |
Why?
|
| Splenomegaly | 1 | 1980 | 34 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2005 | 518 | 0.040 |
Why?
|
| Renal Veins | 1 | 2019 | 36 | 0.040 |
Why?
|
| Thrombosis | 3 | 2019 | 522 | 0.040 |
Why?
|
| Iliac Vein | 1 | 2019 | 34 | 0.040 |
Why?
|
| Vascular Grafting | 1 | 2019 | 46 | 0.040 |
Why?
|
| Tetrazoles | 1 | 2019 | 68 | 0.040 |
Why?
|
| Hemoglobins | 2 | 2004 | 303 | 0.040 |
Why?
|
| Peritoneum | 1 | 1999 | 36 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2019 | 169 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 192 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 227 | 0.040 |
Why?
|
| Contrast Media | 2 | 2017 | 471 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 334 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 88 | 0.040 |
Why?
|
| Imidazoles | 1 | 2019 | 194 | 0.040 |
Why?
|
| Dihydroxycholecalciferols | 1 | 1977 | 1 | 0.040 |
Why?
|
| Hydroxycholecalciferols | 1 | 1977 | 6 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 2426 | 0.040 |
Why?
|
| Kidney Cortex | 1 | 1977 | 20 | 0.040 |
Why?
|
| Iohexol | 1 | 2017 | 20 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2018 | 256 | 0.040 |
Why?
|
| Length of Stay | 1 | 2023 | 1311 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2016 | 1499 | 0.040 |
Why?
|
| Triiodobenzoic Acids | 1 | 2017 | 28 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 2043 | 0.030 |
Why?
|
| Algorithms | 1 | 2004 | 1618 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2016 | 30 | 0.030 |
Why?
|
| PAX2 Transcription Factor | 1 | 2016 | 27 | 0.030 |
Why?
|
| Proteins | 1 | 2002 | 1045 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2016 | 80 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 237 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1811 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 1999 | 258 | 0.030 |
Why?
|
| Neurotransmitter Agents | 1 | 1976 | 147 | 0.030 |
Why?
|
| Aorta | 1 | 2019 | 537 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2018 | 385 | 0.030 |
Why?
|
| Diagnosis, Differential | 4 | 1999 | 1895 | 0.030 |
Why?
|
| Escherichia coli Infections | 2 | 2002 | 196 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 472 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 366 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2004 | 683 | 0.030 |
Why?
|
| Hematocrit | 2 | 2004 | 111 | 0.030 |
Why?
|
| Texas | 2 | 2017 | 3592 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 555 | 0.030 |
Why?
|
| Academies and Institutes | 1 | 2014 | 83 | 0.030 |
Why?
|
| Prognosis | 2 | 2018 | 4615 | 0.030 |
Why?
|
| Amoxicillin | 1 | 1993 | 121 | 0.030 |
Why?
|
| Hearing Loss, Conductive | 1 | 1992 | 13 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 1595 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2014 | 225 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 1992 | 75 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1782 | 0.020 |
Why?
|
| Dietary Proteins | 1 | 1994 | 250 | 0.020 |
Why?
|
| Hypertension, Renovascular | 1 | 1992 | 29 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 820 | 0.020 |
Why?
|
| Oxygen | 1 | 1975 | 555 | 0.020 |
Why?
|
| Facial Paralysis | 1 | 1991 | 35 | 0.020 |
Why?
|
| Critical Care | 1 | 2016 | 654 | 0.020 |
Why?
|
| Medicare | 1 | 2014 | 424 | 0.020 |
Why?
|
| Vision Disorders | 1 | 1992 | 212 | 0.020 |
Why?
|
| Prospective Studies | 4 | 2004 | 6143 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2016 | 1570 | 0.020 |
Why?
|
| Institutionalization | 1 | 1990 | 15 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1272 | 0.020 |
Why?
|
| Intubation, Gastrointestinal | 1 | 1990 | 52 | 0.020 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 1989 | 16 | 0.020 |
Why?
|
| Rats, Inbred Strains | 3 | 1983 | 234 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2010 | 177 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 1992 | 335 | 0.020 |
Why?
|
| Neoplasms | 1 | 2003 | 2788 | 0.020 |
Why?
|
| Administration, Sublingual | 1 | 1988 | 12 | 0.020 |
Why?
|
| Rats | 5 | 1983 | 3695 | 0.020 |
Why?
|
| Aleutian Mink Disease | 1 | 1988 | 1 | 0.020 |
Why?
|
| Mink | 1 | 1988 | 3 | 0.020 |
Why?
|
| Fibrin | 1 | 1988 | 65 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 1988 | 121 | 0.020 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 1988 | 9 | 0.020 |
Why?
|
| Blindness | 1 | 1988 | 72 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2630 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 4788 | 0.020 |
Why?
|
| Cross Infection | 1 | 1990 | 330 | 0.020 |
Why?
|
| Citrates | 1 | 1986 | 22 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 1988 | 218 | 0.020 |
Why?
|
| Quality Control | 1 | 2005 | 119 | 0.020 |
Why?
|
| Pain | 1 | 1988 | 462 | 0.020 |
Why?
|
| Reimbursement Mechanisms | 1 | 2005 | 36 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2005 | 63 | 0.010 |
Why?
|
| Lactation | 1 | 1986 | 194 | 0.010 |
Why?
|
| Transferrin | 1 | 2004 | 51 | 0.010 |
Why?
|
| Fatty Acids | 1 | 1986 | 351 | 0.010 |
Why?
|
| Urination Disorders | 1 | 1983 | 18 | 0.010 |
Why?
|
| Absorption | 1 | 1983 | 52 | 0.010 |
Why?
|
| Ferritins | 1 | 2004 | 97 | 0.010 |
Why?
|
| Iothalamic Acid | 1 | 2003 | 3 | 0.010 |
Why?
|
| Diuresis | 1 | 1983 | 58 | 0.010 |
Why?
|
| Milk, Human | 1 | 1986 | 301 | 0.010 |
Why?
|
| Urine | 1 | 1983 | 90 | 0.010 |
Why?
|
| Erythropoietin | 1 | 2004 | 104 | 0.010 |
Why?
|
| Urinary Catheterization | 1 | 1983 | 81 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2003 | 143 | 0.010 |
Why?
|
| Radiography | 2 | 1988 | 829 | 0.010 |
Why?
|
| Escherichia coli O157 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Cystinosis | 1 | 1982 | 15 | 0.010 |
Why?
|
| Hepatitis B Antibodies | 1 | 2002 | 24 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 550 | 0.010 |
Why?
|
| Intellectual Disability | 1 | 1990 | 1061 | 0.010 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2002 | 101 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 101 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2005 | 391 | 0.010 |
Why?
|
| Infarction | 1 | 1982 | 23 | 0.010 |
Why?
|
| Self Care | 1 | 1983 | 214 | 0.010 |
Why?
|
| Animals | 7 | 1988 | 34207 | 0.010 |
Why?
|
| Complement C4 | 1 | 1981 | 5 | 0.010 |
Why?
|
| Hypoparathyroidism | 1 | 1981 | 11 | 0.010 |
Why?
|
| Carotid Artery, Internal | 1 | 1982 | 67 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1988 | 1153 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2002 | 343 | 0.010 |
Why?
|
| Complement C3 | 1 | 1981 | 48 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2005 | 634 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1981 | 75 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 1193 | 0.010 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1981 | 82 | 0.010 |
Why?
|
| Urinary Tract | 1 | 1981 | 60 | 0.010 |
Why?
|
| Wounds, Penetrating | 1 | 1981 | 141 | 0.010 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2005 | 481 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2005 | 496 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1986 | 430 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1395 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 1981 | 93 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1980 | 102 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 2002 | 374 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 2038 | 0.010 |
Why?
|
| Cadaver | 1 | 2000 | 129 | 0.010 |
Why?
|
| Gastroenteritis | 1 | 2002 | 349 | 0.010 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1981 | 171 | 0.010 |
Why?
|
| Carcinoma | 1 | 1981 | 285 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 1981 | 199 | 0.010 |
Why?
|
| Genes, myc | 1 | 1999 | 100 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2004 | 1351 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1981 | 293 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1999 | 356 | 0.010 |
Why?
|
| Syndrome | 2 | 1992 | 1119 | 0.010 |
Why?
|
| Acetazolamide | 1 | 1977 | 30 | 0.010 |
Why?
|
| Neurochemistry | 1 | 1976 | 5 | 0.010 |
Why?
|
| Aged | 2 | 1988 | 19712 | 0.010 |
Why?
|
| Acute Disease | 1 | 2000 | 1109 | 0.010 |
Why?
|
| Anemia, Sickle Cell | 1 | 1980 | 336 | 0.010 |
Why?
|
| Digitoxin | 1 | 1975 | 7 | 0.010 |
Why?
|
| Microsomes, Liver | 1 | 1975 | 89 | 0.010 |
Why?
|
| Diphosphoglyceric Acids | 1 | 1975 | 4 | 0.010 |
Why?
|
| Carbon Monoxide Poisoning | 1 | 1975 | 7 | 0.010 |
Why?
|
| Middle Aged | 2 | 1988 | 26756 | 0.010 |
Why?
|
| Partial Pressure | 1 | 1975 | 28 | 0.010 |
Why?
|
| Hydrogen | 1 | 1975 | 41 | 0.010 |
Why?
|
| Oxyhemoglobins | 1 | 1975 | 24 | 0.010 |
Why?
|
| Altitude | 1 | 1975 | 23 | 0.010 |
Why?
|
| Southwestern United States | 1 | 1994 | 43 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1975 | 309 | 0.010 |
Why?
|
| California | 1 | 1994 | 130 | 0.010 |
Why?
|
| Schizophrenia | 1 | 1976 | 302 | 0.010 |
Why?
|
| Drug Overdose | 1 | 1993 | 66 | 0.010 |
Why?
|
| Hypoxia | 1 | 1975 | 247 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1975 | 309 | 0.010 |
Why?
|
| Disease Progression | 1 | 1999 | 2052 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 1975 | 359 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1977 | 780 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 1975 | 232 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 1994 | 307 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1994 | 366 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1994 | 762 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1975 | 673 | 0.010 |
Why?
|
| Mice | 1 | 1988 | 17749 | 0.010 |
Why?
|
| Foodborne Diseases | 1 | 1990 | 11 | 0.010 |
Why?
|
| Utah | 1 | 1990 | 47 | 0.010 |
Why?
|
| Diarrhea, Infantile | 1 | 1990 | 36 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1990 | 250 | 0.010 |
Why?
|
| Parkinson Disease | 1 | 1976 | 694 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1994 | 778 | 0.000 |
Why?
|
| Retinal Artery | 1 | 1988 | 16 | 0.000 |
Why?
|
| Cerebral Infarction | 1 | 1988 | 46 | 0.000 |
Why?
|
| Disease Outbreaks | 1 | 1990 | 323 | 0.000 |
Why?
|
| Diarrhea | 1 | 1990 | 317 | 0.000 |
Why?
|
| Epoprostenol | 1 | 1988 | 67 | 0.000 |
Why?
|
| Lung | 1 | 1975 | 1487 | 0.000 |
Why?
|
| Horses | 1 | 1986 | 90 | 0.000 |
Why?
|
| Colostrum | 1 | 1986 | 56 | 0.000 |
Why?
|
| Feces | 1 | 1990 | 720 | 0.000 |
Why?
|
| Sheep | 1 | 1986 | 217 | 0.000 |
Why?
|
| Retinal Diseases | 1 | 1988 | 172 | 0.000 |
Why?
|
| Cattle | 1 | 1986 | 568 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1990 | 988 | 0.000 |
Why?
|
| Prune Belly Syndrome | 1 | 1983 | 5 | 0.000 |
Why?
|
| Urinary Diversion | 1 | 1983 | 43 | 0.000 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 1983 | 46 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 1990 | 3290 | 0.000 |
Why?
|
| Pigmentation | 1 | 1982 | 35 | 0.000 |
Why?
|
| Longitudinal Studies | 1 | 1986 | 1328 | 0.000 |
Why?
|
| Carotid Artery Thrombosis | 1 | 1982 | 4 | 0.000 |
Why?
|
| Inulin | 1 | 1982 | 18 | 0.000 |
Why?
|
| Jugular Veins | 1 | 1982 | 76 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1982 | 153 | 0.000 |
Why?
|
| Phenobarbital | 1 | 1981 | 36 | 0.000 |
Why?
|
| Pregnancy | 2 | 1986 | 7178 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1982 | 396 | 0.000 |
Why?
|
| Necrosis | 1 | 1982 | 206 | 0.000 |
Why?
|
| Tracheotomy | 1 | 1981 | 35 | 0.000 |
Why?
|
| Hypocalcemia | 1 | 1981 | 37 | 0.000 |
Why?
|
| Thyroxine | 1 | 1981 | 69 | 0.000 |
Why?
|
| Pregnancy Trimester, First | 1 | 1981 | 114 | 0.000 |
Why?
|
| Meningomyelocele | 1 | 1983 | 239 | 0.000 |
Why?
|
| Trachea | 1 | 1981 | 201 | 0.000 |
Why?
|
| Head and Neck Neoplasms | 1 | 1981 | 499 | 0.000 |
Why?
|
| Digitoxigenin | 1 | 1975 | 6 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1975 | 41 | 0.000 |
Why?
|
| Hydroxylation | 1 | 1975 | 45 | 0.000 |
Why?
|
| NADP | 1 | 1975 | 49 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1975 | 973 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1981 | 1668 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1982 | 4359 | 0.000 |
Why?
|